[{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xellia Pharmaceuticals expands approved doses of VANCO READY\u2122 (Ready-to-use Premixed Vancomycin bags)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Xellia Pharmaceuticals ApS"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Positive Topline Results from Phase 3 Clinical Study of Freeze-dried Smallpox Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Health Emergency Preparedness and Response Authority","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine For Monkeypox Preparedness","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"HERA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeypox Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Danske Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic A\/S Launches Offering of up to 7,046,839 New Shares in a Directed Issue","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"European Union","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic\u2019s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) is approved for the prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox and mpox infection.
Lead Product(s):
Live Nonreplicating Smallpox and Monkeypox Vaccine
Under the agreement, Bavarian will supply its Imvanex (MVA-BN or modified vaccinia ankara ) non-replicating smallpox vaccine to rescEU, a strategic reserve within the European Union.
The net proceeds from the Offering are intended to be used for payment of the purchase price in respect of the Company’s contemplated acquisition of a portfolio of travel vaccines including Vivotif (typhoid vaccine) from Emergent BioSolutions.
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government.
IMVANEX® (MVA-BN) is a non-replicating smallpox vaccine, to ensure supply of smallpox vaccine for entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines.
IMVANEX® (MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic) is a non-replicating smallpox vaccine, that is extended to include protecting people from monkeypox disease.
BARDA supported the development of JYNNEOS, which is approved by the FDA to prevent smallpox and monkeypox. The U.S. government owns enough smallpox vaccine – JYNNEOS and ACAM2000 – to vaccinate millions of Americans.
Lead Product(s):
Live Nonreplicating Smallpox and Monkeypox Vaccine
MVA-BN or Modified Vaccinia Ankara (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population.
Bavarian Nordic’s smallpox vaccine is approved in the U.S as JYNNEOS and in Canada as IMVAMUNE, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe as IMVANEX (Live Modified Vaccinia Virus Ankara) for smallpox indication.
Lead Product(s):
Live Modified Vaccinia Virus Ankara
MVA-BN, (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and patented vaccine platform technology, robust and adaptable platform suitable for addressing a wide variety of infectious diseases and cancers.